Dexamethasone at discharge for COVID-19 does not reduce readmission, mortality

Continued use of dexamethasone after hospital discharge was not associated with a reduction in readmission or mortality among patients with COVID-19, researchers reported in JAMA Network Open.
Cheng-Wei Huang, MD, a physician at Kaiser Permanente Los Angeles Medical Center, and colleagues conducted a retrospective cohort study at 15 medical centers within Kaiser Permanente’s Southern California locations.
They enrolled 1,164 adults aged 18 years or older who were discharged after being hospitalized for COVID-19 between May 1 and Sept. 30, 2020. All participants received less than 10 days

Continued use of dexamethasone after hospital discharge was not associated with a reduction in readmission or mortality among patients with COVID-19, researchers reported in JAMA Network Open.
Cheng-Wei Huang, MD, a physician at Kaiser Permanente Los Angeles Medical Center, and colleagues conducted a retrospective cohort study at 15 medical centers within Kaiser Permanente’s Southern California locations.
They enrolled 1,164 adults aged 18 years or older who were discharged after being hospitalized for COVID-19 between May 1 and Sept. 30, 2020. All participants received less than 10 days